Coronavirus vaccine makers such as Moderna (MRNA), BioNTech (BNTX) and Pfizer (PFE) were big winners. Both Moderna stock and BioNTech could be deemed early entries. But investors might want to see more strength from Moderna and a post-gap up consolidation from BNTX stock. Coronavirus Vaccine Stocks Pfizer and partner BioNTech, along with rival mRNA coronavirus vaccine maker Moderna, jumped on the Omicron Covid variant, also called Nu Covid. MRNA stock gapped above its 50-day line, breaking a trend line with a 21% gain.
New Covid variant: It is one of three strategies the company is working to combat the new corona variant, including a higher dose of its existing vaccine, Moderna said
CEO of Moderna Inc (30-Year Financial, Insider Trades) Stephane Bancel (insider trades) sold 9,000 shares of MRNA on 11/24/2021 at an average price of $273.01 a share. The total sale was $2.5 million. For the complete insider trading history of MRNA, click here
Data is expected in the coming weeks, the statement noted
Story continues below advertisement Moderna Inc said in a statement it is working to advance a booster candidate tailored to the new variant and has also been testing a higher dose of its existing booster and to study other booster candidates designed to protect against multiple variants. “A booster dose of an authorized vaccine represents the only currently available strategy for boosting waning immunity,” Moderna said in the statement. Moderna gained 20.6 per cent to close at $329.63. Send this page to someone via email BioNTech SE said on Friday it expects more data on a worrying new coronavirus variant detected in South Africa within two weeks to help determine whether its vaccine produced with partner Pfizer Inc would have to be reworked. Pfizer and BioNTech said that if necessary they expect to be able to ship a new vaccine tailored to the emerging variant in approximately 100 days.
The US pharmaceutical company Moderna said Friday it will develop a booster shot against the new Omicron variant of the coronavirus.
Moderna Inc. undefined said Friday it will "rapidly advance" an omicron-specific COVID-19 booster vaccine candidate and continue to work on booster...
Moderna Inc. revealed on Friday that it "will rapidly advance" a booster candidate of its coronavirus vaccine that would specifically fight the Omicron variant of the disease. The Massachus
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
Investors sought shelter in the COVID-19 vaccine maker's shares.
The Dow Jones suffered its worst day of 2021 amid new Covid fears. Moderna stock popped. A Warren Buffett stock rebounded higher.
CNBC's Meg Tirell (pictured) reports that Pfizer and Moderna both are taking action to potentially update their COVID-19 vaccines if need be in wake of the newly discovered South African virus strain The new strain has over 30 mutations, it what has been described as a 'constellation' by some 'Moderna and BioNTech and Pfizer tell us that they are already looking at this very closely and have told us they can update the vaccines very quickly if they need to' CNBC's Meg Tirell said on TechCheck Friday. More than 108 million Americans have been fully vaccinated by the Pfizer-BioNTech vaccine, and 71.5 million by the Moderna shot according to data published Wednesday by the U.S. Centers for Disease Control and Prevention (CDC). Pfizer and Moderna both report that they can get out updated vaccines in the coming months if needed. Pictured: vials of the Pfizer and Moderna COVID-19 vaccines Because of the new nature of the variant, not much is known about it yet. Pfizer, its vaccine partner BioNTech and Moderna, who are responsible for producing the two most common vaccines in the U.S., have all said they can quickly update the vaccines to provide protection against the emerging variant, if necessary.
- Page 1 of 64.